TLR9 and neoplasm: Most strikingly, TLR9 agonists like cytosine-phosphate-guanine (CpG) oligonucleotides that showed promising anti-tumor immunity in mice caused severe adverse events in human trials due to the broader TLR9 expression on human immune cells [118,119,120,121,122].